Stock data

杏昌 (1788)

杏昌 is a TPEx-listed company in Biotech & Medical Care. Revenue for September 2026 was NT$414.84M, up 14.9% from a year earlier. EPS over the last four quarters totals NT$8.81.

Charts, drawing tools, and the P/E calculator are in the app, free to use.

Open 杏昌 in Insightr